

Paul W Denton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8358217/publications.pdf>

Version: 2024-02-01

63
papers

4,167
citations

186209

28
h-index

138417

58
g-index

67
all docs

67
docs citations

67
times ranked

3974
citing authors

#	ARTICLE	IF	CITATIONS
1	The size and culturability of patient-generated SARS-CoV-2 aerosol. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2022, 32, 706-711.	1.8	87
2	Helminth products modulate innate immune recognition of nucleic acids in systemic lupus erythematosus. <i>Lupus</i> , 2022, 31, 415-423.	0.8	1
3	HIV cure trial mergers: Spotlighting the epigenetics of latency reversal. <i>EBioMedicine</i> , 2022, 79, 104012.	2.7	1
4	Poor compliance with an antibiotic directive—A call for intensified monitoring. <i>International Journal of Infectious Diseases</i> , 2021, 104, 474-478.	1.5	0
5	Predicting Cognitive Rehabilitation Needs in Patients with Central Nervous System Infections Using Montreal Cognitive Assessment. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1350-1357.	0.3	3
6	Modest de novo Reactivation of Single HIV-1 Proviruses in Peripheral CD4+ T Cells by Romidepsin. <i>Frontiers in Virology</i> , 2021, 1, .	0.7	1
7	Sialylation and fucosylation modulate inflammasome-activating eIF2 Signaling and microbial translocation during HIV infection. <i>Mucosal Immunology</i> , 2020, 13, 753-766.	2.7	24
8	Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	6
9	Comparable human reconstitution following Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice. <i>PLoS ONE</i> , 2020, 15, e0241375.	1.1	7
10	TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes. <i>EBioMedicine</i> , 2019, 45, 328-340.	2.7	22
11	Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues. <i>Frontiers in Microbiology</i> , 2019, 10, 1956.	1.5	14
12	Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption. <i>Journal of Virology</i> , 2019, 93, .	1.5	49
13	<sc>cAIMP</sc> administration in humanized mice induces a chimerization—level—dependent <sc>STING</sc> response. <i>Immunology</i> , 2019, 157, 163-172.	2.0	6
14	Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation. <i>Journal of Virus Eradication</i> , 2019, 5, 133-137.	0.3	13
15	Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals. <i>Aids</i> , 2019, 33, 1315-1325.	1.0	66
16	Non-covalent hitchhiking on endogenous carriers as a protraction mechanism for antiviral macromolecular prodrugs. <i>Journal of Controlled Release</i> , 2019, 294, 298-310.	4.8	17
17	Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency without T cell activation. <i>Journal of Virus Eradication</i> , 2019, 5, 133-137.	0.3	6
18	Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits <i>Ex Vivo</i> Lipopolysaccharide-Induced Inflammatory Responses. <i>MSphere</i> , 2018, 3, .	1.3	17

#	ARTICLE	IF	CITATIONS
19	Acute Appendicitis as the Initial Clinical Presentation of Primary HIV-1 Infection. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy006.	0.4	4
20	Long-Acting, Potent Delivery of Combination Antiretroviral Therapy. <i>ACS Macro Letters</i> , 2018, 7, 587-591.	2.3	15
21	The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon. <i>Mucosal Immunology</i> , 2018, 11, 449-461.	2.7	31
22	Interferon priming is essential for human CD34+ cell-derived plasmacytoid dendritic cell maturation and function. <i>Nature Communications</i> , 2018, 9, 3525.	5.8	37
23	Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals. <i>Aids</i> , 2018, 32, 1793-1802.	1.0	10
24	Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. <i>Scientific Reports</i> , 2017, 7, 41098.	1.6	8
25	Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2017, 64, 1686-1695.	2.9	122
26	Predictive value of galectin-1 in the development and progression of HIV-associated lymphoma. <i>Aids</i> , 2017, 31, 2311-2313.	1.0	2
27	The role of miR-29a in HIV-1 replication and latency. <i>Journal of Virus Eradication</i> , 2017, 3, 185-191.	0.3	10
28	The role of miR-29a in HIV-1 replication and latency. <i>Journal of Virus Eradication</i> , 2017, 3, 185-191.	0.3	5
29	HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy. <i>Aids</i> , 2016, 30, 713-721.	1.0	19
30	Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research. <i>Journal of Translational Medicine</i> , 2016, 14, 44.	1.8	15
31	Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. <i>Lancet HIV</i> , 2016, 3, e463-e472.	2.1	159
32	Broad activation of latent HIV-1 in vivo. <i>Nature Communications</i> , 2016, 7, 12731.	5.8	65
33	A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4 ⁺ T Cells. <i>Journal of Virology</i> , 2016, 90, 4441-4453.	1.5	94
34	ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions. <i>Journal of Clinical Investigation</i> , 2016, 126, 892-904.	3.9	30
35	Immune checkpoints and the HIV-1 reservoir: proceed with caution. <i>Journal of Virus Eradication</i> , 2016, 2, 183-6.	0.3	12
36	The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. <i>PLoS Pathogens</i> , 2015, 11, e1005142.	2.1	445

#	ARTICLE	IF	CITATIONS
37	Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients. <i>Mediators of Inflammation</i> , 2015, 2015, 1-11.	1.4	10
38	Histone Deacetylase Inhibitor Romidepsin Inhibits <i>De Novo</i> HIV-1 Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3984-3994.	1.4	26
39	Hypogammaglobulinemia in BLT Humanized Mice – An Animal Model of Primary Antibody Deficiency. <i>PLoS ONE</i> , 2014, 9, e108663.	1.1	20
40	Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART. <i>PLoS Pathogens</i> , 2014, 10, e1003872.	2.1	101
41	Impact of the Mouse IL-2R β Chain on Lymphoid Tissue Development and Human Reconstitution in Immunodeficient Mice. , 2014, , 61-73.		1
42	Vaginal and Rectal HIV Transmission in Humanized Mice. , 2014, , 235-245.		0
43	Cryptopatches Are Essential for the Development of Human GALT. <i>Cell Reports</i> , 2013, 3, 1874-1884.	2.9	58
44	In vivo analysis of highly conserved Nef activities in HIV-1 replication and pathogenesis. <i>Retrovirology</i> , 2013, 10, 125.	0.9	26
45	Rectal Transmission of Transmitted/Founder HIV-1 Is Efficiently Prevented by Topical 1% Tenofovir in BLT Humanized Mice. <i>PLoS ONE</i> , 2013, 8, e60024.	1.1	54
46	Human Breast Milk and Antiretrovirals Dramatically Reduce Oral HIV-1 Transmission in BLT Humanized Mice. <i>PLoS Pathogens</i> , 2012, 8, e1002732.	2.1	82
47	IL-2 receptor β -chain molecule is critical for intestinal T-cell reconstitution in humanized mice. <i>Mucosal Immunology</i> , 2012, 5, 555-566.	2.7	85
48	Generation of HIV Latency in Humanized BLT Mice. <i>Journal of Virology</i> , 2012, 86, 630-634.	1.5	180
49	Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. <i>Trends in Microbiology</i> , 2012, 20, 268-274.	3.5	60
50	Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes. <i>Retrovirology</i> , 2012, 9, 44.	0.9	60
51	Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection. <i>Journal of Reproductive Immunology</i> , 2011, 88, 195-203.	0.8	60
52	One Percent Tenofovir Applied Topically to Humanized BLT Mice and Used According to the CAPRISA 004 Experimental Design Demonstrates Partial Protection from Vaginal HIV Infection, Validating the BLT Model for Evaluation of New Microbicide Candidates. <i>Journal of Virology</i> , 2011, 85, 7582-7593.	1.5	133
53	Humanized mouse models of HIV infection. <i>AIDS Reviews</i> , 2011, 13, 135-48.	0.5	135
54	Systemic Administration of Antiretrovirals Prior to Exposure Prevents Rectal and Intravenous HIV-1 Transmission in Humanized BLT Mice. <i>PLoS ONE</i> , 2010, 5, e8829.	1.1	148

#	ARTICLE	IF	CITATIONS
55	Novel humanized murine models for HIV research. <i>Current HIV/AIDS Reports</i> , 2009, 6, 13-19.	1.1	66
56	Functional and Phenotypic Characterization of the Humanized BLT Mouse Model. <i>Current Topics in Microbiology and Immunology</i> , 2008, 324, 149-165.	0.7	113
57	Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice. <i>PLoS Medicine</i> , 2008, 5, e16.	3.9	291
58	Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. <i>Journal of Experimental Medicine</i> , 2007, 204, 705-714.	4.2	256
59	Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. <i>Nature Medicine</i> , 2006, 12, 1316-1322.	15.2	590
60	Inhibition of Lysosome and Proteasome Function Enhances Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2005, 79, 5705-5712.	1.5	100
61	CD8 + T cells reduce in vitro interferon-g production in Theiler's murine encephalomyelitis virus-induced demyelinating disease model. <i>Multiple Sclerosis Journal</i> , 2004, 10, 370-375.	1.4	0
62	Susceptibility to Theiler's murine encephalomyelitis virus-induced demyelinating disease in BALB/cAnNCr mice is related to absence of a CD4+ T-cell subset. <i>Multiple Sclerosis Journal</i> , 2002, 8, 469-474.	1.4	15
63	CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	1